Community and Close Contact Exposures Associated with COVID-19 Among Symptomatic Adults ≥18 Years in 11 Outpatient Health Care Facilities - United States, July 2020.


Journal

MMWR. Morbidity and mortality weekly report
ISSN: 1545-861X
Titre abrégé: MMWR Morb Mortal Wkly Rep
Pays: United States
ID NLM: 7802429

Informations de publication

Date de publication:
11 Sep 2020
Historique:
entrez: 11 9 2020
pubmed: 12 9 2020
medline: 17 9 2020
Statut: epublish

Résumé

Community and close contact exposures continue to drive the coronavirus disease 2019 (COVID-19) pandemic. CDC and other public health authorities recommend community mitigation strategies to reduce transmission of SARS-CoV-2, the virus that causes COVID-19 (1,2). Characterization of community exposures can be difficult to assess when widespread transmission is occurring, especially from asymptomatic persons within inherently interconnected communities. Potential exposures, such as close contact with a person with confirmed COVID-19, have primarily been assessed among COVID-19 cases, without a non-COVID-19 comparison group (3,4). To assess community and close contact exposures associated with COVID-19, exposures reported by case-patients (154) were compared with exposures reported by control-participants (160). Case-patients were symptomatic adults (persons aged ≥18 years) with SARS-CoV-2 infection confirmed by reverse transcription-polymerase chain reaction (RT-PCR) testing. Control-participants were symptomatic outpatient adults from the same health care facilities who had negative SARS-CoV-2 test results. Close contact with a person with known COVID-19 was more commonly reported among case-patients (42%) than among control-participants (14%). Case-patients were more likely to have reported dining at a restaurant (any area designated by the restaurant, including indoor, patio, and outdoor seating) in the 2 weeks preceding illness onset than were control-participants (adjusted odds ratio [aOR] = 2.4; 95% confidence interval [CI] = 1.5-3.8). Restricting the analysis to participants without known close contact with a person with confirmed COVID-19, case-patients were more likely to report dining at a restaurant (aOR = 2.8, 95% CI = 1.9-4.3) or going to a bar/coffee shop (aOR = 3.9, 95% CI = 1.5-10.1) than were control-participants. Exposures and activities where mask use and social distancing are difficult to maintain, including going to places that offer on-site eating or drinking, might be important risk factors for acquiring COVID-19. As communities reopen, efforts to reduce possible exposures at locations that offer on-site eating and drinking options should be considered to protect customers, employees, and communities.

Identifiants

pubmed: 32915165
doi: 10.15585/mmwr.mm6936a5
pmc: PMC7499837
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

1258-1264

Subventions

Organisme : NIGMS NIH HHS
ID : K23 GM129661
Pays : United States
Organisme : NHLBI NIH HHS
ID : K23 HL153584
Pays : United States
Organisme : NIAID NIH HHS
ID : K24 AI148459
Pays : United States
Organisme : NHLBI NIH HHS
ID : T32 HL087738
Pays : United States

Investigateurs

Kimberly W Hart (KW)
Robert McClellan (R)
Hsi-Nien Tan (HN)
Adrienne Baughman (A)
Nora A Hennesy (NA)
Brittany Grear (B)
Michael Wu (M)
Kristin Mlynarczyk (K)
Luc Marzano (L)
Zuwena Plata (Z)
Alexis Caplan (A)
Samantha M Olson (SM)
Constance E Ogokeh (CE)
Emily R Smith (ER)
Sara S Kim (SS)
Eric P Griggs (EP)
Bridget Richards (B)
Sonya Robinson (S)
Kaylee Kim (K)
Ahmed M Kassem (AM)
Courtney N Sciarratta (CN)
Paula L Marcet (PL)

Commentaires et corrections

Type : ErratumIn

Déclaration de conflit d'intérêts

All authors have completed and submitted the International Committee of Medical Journal Editors form for disclosure of potential conflicts of interest. Carlos G. Grijalva reports grants from Campbell Alliance, the National Institutes of Health, the Food and Drug Administration, the Agency for Health Care Research and Quality and Sanofi-Pasteur, and consultation fees from Pfizer, Merck, and Sanofi-Pasteur. Christopher J. Lindsell reports grants from National Institutes of Health and the Department of Defense and other support from Marcus Foundation, Endpoint Health, Entegrion, bioMerieux, and Bioscape Digital, outside the submitted work. Nathan I. Shapiro reports grants from the National Institutes of Health, Rapid Pathogen Screening, Inflammatix, and Baxter, outside the submitted work. Daniel J. Henning reports personal fees from CytoVale and grants from Baxter, outside the submitted work. Samuel M. Brown reports grants from National Institutes of Health, Department of Defense, Intermountain Research and Medical Foundation, and Janssen and consulting fees paid to his employer from Faron and Sedana, outside the submitted work. Ithan D. Peltan reports grants from the National Institutes of Health, Asahi Kasei Pharma, Immunexpress Inc., Janssen Pharmaceuticals, and Regeneron, outside the submitted work. Todd W. Rice reports personal fees from Cumberland Pharmaceuticals, Inc, Cytovale, Inc, and Avisa, LLC, outside the submitted work. Adit A. Ginde reports grants from the National Institutes of Health and Department of Defense, outside the submitted work. H. Keipp Talbot reports serving on the Data Safety Monitoring Board for Seqirus. No other potential conflicts of interest were disclosed.

Références

MMWR Morb Mortal Wkly Rep. 2020 Jul 03;69(26):841-846
pubmed: 32614810
Expert Rev Mol Diagn. 2020 May;20(5):453-454
pubmed: 32297805
Clin Infect Dis. 2020 Jul 06;:
pubmed: 32628750
MMWR Morb Mortal Wkly Rep. 2020 Jul 03;69(26):847-849
pubmed: 32614809
Emerg Infect Dis. 2020 Jul;26(7):1628-1631
pubmed: 32240078
J Biomed Inform. 2019 Jul;95:103208
pubmed: 31078660
JAMA. 2020 Jun 9;323(22):2249-2251
pubmed: 32374370
J Infect. 2020 Aug 25;:
pubmed: 32858069

Auteurs

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH